Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications
Toxins · 25.03.2025 · 17 (4) · 163
DOI: 10.3390/toxins17040163 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxins, online erschienen am 25.03.2025. Verfasst von Sofia M Perez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Scalp Dermatoses, Hair Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Botulinum toxin (BoNT) is well-recognized throughout dermatology for its cosmetic indications and growing therapeutic value. Recent studies have trialed BoNT in the treatment of hair and scalp disorders, many of which lack long-term effective treatments and significantly impact quality of life. In this review, we summarize the current clinical literature on this topic to comprehensively evaluate the efficacy, safety, and clinical value of BoNT in treating hair and scalp conditions. A literature search on PubMed/MEDLINE and Scopus identified 40 articles reporting the use of 25–200 units of BoNT-A or B in 689 patients with hair loss (79.5%), scalp seborrheic dermatitis/hyperseborrhea (10%), craniofacial hyperhidrosis (9%), folliculitis decalvans/dissecting folliculitis (0.86%), scalp pain (0.43%), or linear scleroderma (0.29%). Most studies on BoNT therapy for androgenetic alopecia (AGA) reported mild or non-significant hair growth; however, considerable variability in outcome measures complicates the ability to draw definitive conclusions or justify the use of BoNT over established AGA therapies. BoNT-A and B showed consistent efficacy in treating craniofacial hyperhidrosis with minimal side effects. Additional scalp conditions may benefit from BoNT therapy, but the evidence is limited, and larger, controlled studies are needed to better understand BoNT’s clinical value in these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Department of Dermatology, King Abdulaziz Medical City, Riyadh 22490, Saudi Arabia.
ORCID-Profile: Sofia M Perez, Betty Nguyen
Zitieren
APA
Perez, S. M., AlSalman, S. A., Nguyen, B., & Tosti, A. (2025). Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications. Toxins, 17(4), 163. https://doi.org/10.3390/toxins17040163
Vancouver
Perez SM, AlSalman SA, Nguyen B, Tosti A. Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications. Toxins. 2025;17(4):163. doi:10.3390/toxins17040163
BibTeX
@article{Perez2025,
author = {Perez, Sofia M and AlSalman, Sarah A and Nguyen, Betty and Tosti, Antonella},
title = {Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications},
journal = {Toxins},
year = {2025},
volume = {17},
number = {4},
pages = {163},
doi = {10.3390/toxins17040163}
}
EUVIMED